JP2000507833A - B7タンパク質の発現を調節するためのオリゴヌクレオチド組成物および方法 - Google Patents
B7タンパク質の発現を調節するためのオリゴヌクレオチド組成物および方法Info
- Publication number
- JP2000507833A JP2000507833A JP10530085A JP53008598A JP2000507833A JP 2000507833 A JP2000507833 A JP 2000507833A JP 10530085 A JP10530085 A JP 10530085A JP 53008598 A JP53008598 A JP 53008598A JP 2000507833 A JP2000507833 A JP 2000507833A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- group
- protein
- oligonucleotides
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.共有結合によって連結された8〜30個のヌクレオチドを含むオリゴヌ クレオチドであって、B7タンパク質をコードする核酸と特異的にハイブリダイ ズし得る配列を有し、かつ前記B7タンパク質の発現を調節するオリゴヌクレオ チド。 2.共有結合の少なくとも1つが修飾された共有結合である、請求項1のオ リゴヌクレオチド。 3.修飾された共有結合がホスホロチオエート結合、ホスホトリエステル結 合、メチルホスホネート結合、メチレン(メチルイミノ)結合、モルホリノ結合 、アミド結合、ポリアミド結合、短鎖アルキル糖間結合、シクロアルキル糖間結 合、短鎖ヘテロ原子糖間結合及び複素環糖間結合からなる群より選択される、請 求項2のオリゴヌクレオチド。 4.ヌクレオチドの少なくとも1つが修飾された糖部分を有する、請求項1 のオリゴヌクレオチド。 5.修飾された糖部分が、ヌクレオチドの2'位、3'末端ヌクレオチドの3 '位又は5'末端オリゴヌクレオチドの5'位での修飾である、請求項4のオリゴ ヌクレオチド。 6.修飾が、3'ヒドロキシル基のアジド基での置換及び3'もしくは5'ヒ ドロキシル基の水素での置換からなる群より選択される、請求項5のオリゴヌク レオチド。 7.修飾が、2'位での、−OH、−SH、−SCH3、−F、−OCN、− OCH3OCH3、−OCH3O(CH2)nCH3、−O(CH2)nNH2もしくは−O( CH2)nCH3(ここで、nは1〜約10である)、C1〜C10低級アルキル基、 アルコキシアルコキシ基、置換低級アルキル基、置換アルカリール基、置換アラ ルキル基、−Cl、−Br、−CN、−CF3、−OCF3、−O−アルキル基、 −S−アルキル基、−N−アルキル基、O−アルケニル基、S−アルケニル基、 N−アルケニル基、−SOCH3、−SO2CH3、−ONO2、−NO2、−N3、 −NH2、ヘテロシクロアルキル基、ヘテロシクロアルカリール基、アミノアル キルアミノ基、ポリアルキルアミノ基、置換シリル基、RNA開裂基、リポータ ー基、DNA介在基、オリゴヌクレオチドの薬物動態特性を改善するための基、 オリゴヌクレオチドの薬力学的特性を改善するための基、メトキシエトキシ基及 びメトキシ基からなる群より選択される部分の置換又は付加である、請求項5の オリゴヌクレオチド。 8.ヌクレオチドの少なくとも1つが修飾されたヌクレオベースを有する、 請求項1のオリゴヌクレオチド。 9.修飾されたヌクレオベースが、ヒポキサンチン、5−メチルシトシン、 5−ヒドロキシメチルシトシン、グリコシル5−ヒドロキシメチルシトシン、ゲ ンチオビオシル5−ヒドロキシメチルシトシン、5−ブロモウラシル、5−ヒド ロキシメチルウラシル、6−メチルアデニン、N6−(6−アミノヘキシル)アデ ニン、8−アザグアニン、7−デアザグアニン及び2,6−ジアミノプリンから なる群より選択される、請求項8のオリゴヌクレオチド。 10.B7タンパク質がヒトB7−1である、請求項1のオリゴヌクレオチド 。 11.配列番号36の配列を含む、請求項10のオリゴヌクレオチド。 12.B7タンパク質がヒトB7−2である、請求項1のオリゴヌクレオチド 。 13.配列番号3、配列番号9又は配列番号16の配列を含む、請求項12の オリゴヌクレオチド。 14.請求項1のオリゴヌクレオチド及び薬学的に許容し得る担体を含む医薬 組成物。 15.オリゴヌクレオチドが、細胞による前記オリゴヌクレオチドの取り込み を強化する少なくとも1つの親油性部分を含む、請求項1のオリゴヌクレオチド 。 16.親油性部分が、コレステロール部分、コレステリル部分、コール酸、チ オエーテル、チオコレステロール、脂肪族鎖、リン脂質、ポリアミン鎖、ポリエ チレングリコール鎖、アダマンタン酢酸鎖、パルミチル部分、オクタデシルアミ ン部分及びヘキシルアミノ−カルボニル−オキシコレステロール部分からなる群 より選択される、請求項15のオリゴヌクレオチド。 17.請求項15のオリゴヌクレオチド及び薬学的に許容し得る担体を含む医 薬組成物。 18.(a)可溶性ICAMタンパク質、抗体−毒素結合体、プレドニゾン、メ チルプレドニゾロン、アザチオプリン、シクロホスファミド、シクロスポリン、 インターフェロン、交感神経模倣薬、ヒスタミンH1受容体アンタゴニスト、及 びヒスタミンH2受容体アンタゴニストからなる群より選択される抗炎症剤又は 免疫抑制剤; (b)請求項1のオリゴヌクレオチド;及び (c)薬学的に許容し得る担体 を含む医薬組成物。 19.(a)共有結合によって連結された8〜30個のヌクレオチドを含むオリ ゴヌクレオチドであって、前記共有結合の少なくとも1つはホスホジエステル結 合以外の結合であり、前記オリゴヌクレオチドはICAMタンパク質をコードす る核酸と特異的にハイブリダイズし得る配列を有し、かつ前記オリゴヌクレオチ ドは前記ICAMタンパク質の発現を調節するオリゴヌクレオチド; (b)請求項1のオリゴヌクレオチド;及び (c)薬学的に許容し得る担体 を含む医薬組成物。 20.(a)請求項10のオリゴヌクレオチド; (b)共有結合によって連結された8〜30個のヌクレオチドを含むオリ ゴヌクレオチドであって、B7−2タンパク質をコードする核酸と特異的にハイ ブリダイズし得る配列を有し、かつ前記B7−2タンパク質の発現を調節するオ リゴヌクレオチド;及び (c)薬学的に許容し得る担体 を含む医薬組成物。 21.(a)可溶性ICAMタンパク質、抗体−毒素結合体、プレドニゾン、メ チルプレドニゾロン、アザチオプリン、シクロホスファミド、シクロスポリン、 インターフェロン、交感神経模倣薬、ヒスタミンH1受容体アンタゴニスト、ヒ スタミンH2受容体アンタゴニスト及びICAMタンパク質の発現を調節するオ リゴヌクレオチドからなる群より選択される抗炎症剤又は免疫抑制剤; (b)請求項10のオリゴヌクレオチド; (c)共有結合によって連結された8〜30個のヌクレオチドを含むオリ ゴヌクレオチドであって、B7−2タンパク質をコードする核酸と特異的にハイ ブリダイズし得る配列を有し、かつ前記B7−2タンパク質の発現を調節するオ リゴヌクレオチド;及び (d)薬学的に許容し得る担体 を含む医薬組成物。 22.細胞又は組織におけるB7タンパク質の発現を調節する方法であって、 前記細胞又は組織を請求項1のオリゴヌクレオチドと接触させることを含んでな る方法。 23.動物における炎症を治療する方法であって、前記動物に治療上有効な量 の請求項1のオリゴヌクレオチドを投与することを含んでなる方法。 24.動物における自己免疫疾患を治療する方法であって、前記動物に治療上 有効な量の請求項1のオリゴヌクレオチドを投与することを含んでなる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/777,266 US6077833A (en) | 1996-12-31 | 1996-12-31 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US08/777,266 | 1996-12-31 | ||
PCT/US1997/023270 WO1998029124A1 (en) | 1996-12-31 | 1997-12-16 | Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000507833A true JP2000507833A (ja) | 2000-06-27 |
JP3471025B2 JP3471025B2 (ja) | 2003-11-25 |
Family
ID=25109768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53008598A Expired - Fee Related JP3471025B2 (ja) | 1996-12-31 | 1997-12-16 | B7タンパク質の発現を調節するためのオリゴヌクレオチド組成物および方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6077833A (ja) |
EP (1) | EP0957926B1 (ja) |
JP (1) | JP3471025B2 (ja) |
KR (1) | KR100452105B1 (ja) |
AT (1) | ATE289200T1 (ja) |
AU (1) | AU720969B2 (ja) |
CA (1) | CA2274581C (ja) |
DE (1) | DE69732535T2 (ja) |
ES (1) | ES2238083T3 (ja) |
WO (1) | WO1998029124A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033977A1 (en) * | 1990-08-14 | 2004-02-19 | Bennett C. Frank | Oligonucleotide modulation of cell adhesion |
US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6369209B1 (en) * | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
CA2279675A1 (en) * | 1995-12-15 | 1997-06-16 | Enzo Therapeutics, Inc. | Property effecting and/or property exhibiting constructs for localizing a nucleic acid construct within a cell for therapeutic and diagnostic uses |
US7115580B1 (en) * | 1996-12-31 | 2006-10-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of B7 protein expression |
US6319906B1 (en) * | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
US20030165888A1 (en) | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
JP2003517283A (ja) * | 1999-04-08 | 2003-05-27 | オアシス バイオサイエンシーズ インコーポレイティッド | プライマーペアの増幅及び配列決定並びにそれらの使用 |
EP1085085A1 (de) * | 1999-09-18 | 2001-03-21 | Ahmed Dr. Sheriff | Verfahren zur Reduzierung von spezifischen Immunreaktionen |
ATE334193T1 (de) * | 1999-05-04 | 2006-08-15 | Genethor Gmbh | Verfahren zur reduzierung von spezifischen immunreaktionen |
EP2267029B1 (en) | 1999-09-03 | 2016-06-15 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents |
CA2381006A1 (en) * | 1999-09-17 | 2001-03-22 | Nicholas M. Dean | Antisense modulation of transforming growth factor-.beta. expression |
DE60132471T2 (de) * | 2000-09-26 | 2009-01-15 | Idera Pharmaceuticals, Inc., Cambridge | Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen |
US20050019915A1 (en) * | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
EP2221376B1 (en) * | 2001-06-21 | 2012-11-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US20030054354A1 (en) * | 2001-08-23 | 2003-03-20 | Bennett C. Frank | Use of antisense oligonucleotide libraries for identifying gene function |
US20040044404A1 (en) * | 2002-08-30 | 2004-03-04 | Stucke Sean M. | Retention coatings for delivery systems |
US7897582B2 (en) * | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7960355B2 (en) * | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
WO2005017163A2 (en) * | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
US7884085B2 (en) * | 2004-05-12 | 2011-02-08 | Baxter International Inc. | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
EP2072040B1 (en) * | 2004-05-12 | 2013-05-01 | Baxter International Inc. | Therapeutic use of nucleic acid micropheres |
KR100721928B1 (ko) * | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물 |
CN101500616A (zh) | 2006-08-04 | 2009-08-05 | 巴克斯特国际公司 | 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物 |
WO2008131129A2 (en) * | 2007-04-17 | 2008-10-30 | Baxter International Inc. | Nucleic acid microparticles for pulmonary delivery |
US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
EP2524038A4 (en) * | 2010-01-12 | 2013-11-20 | Isis Pharmaceuticals Inc | MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION |
HRP20220798T1 (hr) | 2014-04-01 | 2022-10-14 | Biogen Ma Inc. | Pripravci za modulaciju ekspresije sod-1 |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ209840A (en) * | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5459255A (en) * | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
US5135917A (en) * | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5218105A (en) * | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5138045A (en) * | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5242906A (en) * | 1991-04-22 | 1993-09-07 | University Of North Carolina At Chapel Hill | Antisense oligonucleotides against Epstein-Barr virus |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
JP3722375B2 (ja) * | 1991-06-27 | 2005-11-30 | ブリストル−マイヤーズ スクイブ カンパニー | Ctla4レセプター、それを含有する融合タンパク質およびそれらの使用 |
US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
EP0652972B1 (en) * | 1992-07-20 | 2004-11-17 | Isis Pharmaceuticals, Inc. | Pseudo-half-knot rna formation by hybridization of antisense oligonucleotides to target rna's secondary structure |
US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
CA2107537C (en) * | 1992-10-02 | 2007-01-30 | Lieping Chen | Inhibition of tumor cell growth by administration of b7-transfected cells |
AU7405294A (en) * | 1993-07-26 | 1995-02-20 | Dana-Farber Cancer Institute | B7-2: ctl a4/cd 28 counter receptor |
JPH09501055A (ja) * | 1993-07-30 | 1997-02-04 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 初代リンパ球への効率的遺伝子転移 |
WO1995005464A1 (en) * | 1993-08-16 | 1995-02-23 | Arch Development Corporation | B7-2: ctla4/cd28 counter receptor |
WO1995006738A1 (en) * | 1993-09-03 | 1995-03-09 | Schering Corporation | B70(b7-2):ctla-4 bonding protein |
JPH0779793A (ja) * | 1993-09-14 | 1995-03-28 | Sumitomo Electric Ind Ltd | B70分子に対するモノクローナル抗体 |
CA2188812A1 (en) * | 1994-05-26 | 1995-12-07 | Mark De Boer | New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
JPH10501815A (ja) * | 1994-06-07 | 1998-02-17 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | 抗原特異的t細胞応答の阻害方法 |
AU712714B2 (en) * | 1994-10-03 | 1999-11-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system |
WO1996015780A1 (en) * | 1994-11-23 | 1996-05-30 | Isis Pharmaceuticals, Inc. | Compositions and methods for preventing and treating allograft rejection |
-
1996
- 1996-12-31 US US08/777,266 patent/US6077833A/en not_active Expired - Fee Related
-
1997
- 1997-12-16 ES ES97953268T patent/ES2238083T3/es not_active Expired - Lifetime
- 1997-12-16 WO PCT/US1997/023270 patent/WO1998029124A1/en active IP Right Grant
- 1997-12-16 EP EP97953268A patent/EP0957926B1/en not_active Expired - Lifetime
- 1997-12-16 KR KR10-1999-7005654A patent/KR100452105B1/ko not_active IP Right Cessation
- 1997-12-16 AU AU57051/98A patent/AU720969B2/en not_active Ceased
- 1997-12-16 JP JP53008598A patent/JP3471025B2/ja not_active Expired - Fee Related
- 1997-12-16 CA CA002274581A patent/CA2274581C/en not_active Expired - Fee Related
- 1997-12-16 DE DE69732535T patent/DE69732535T2/de not_active Expired - Lifetime
- 1997-12-16 AT AT97953268T patent/ATE289200T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2274581A1 (en) | 1998-07-09 |
EP0957926B1 (en) | 2005-02-16 |
DE69732535T2 (de) | 2006-03-30 |
EP0957926A4 (en) | 2002-01-23 |
AU720969B2 (en) | 2000-06-22 |
KR100452105B1 (ko) | 2004-10-08 |
WO1998029124A1 (en) | 1998-07-09 |
EP0957926A1 (en) | 1999-11-24 |
ATE289200T1 (de) | 2005-03-15 |
ES2238083T3 (es) | 2005-08-16 |
US6077833A (en) | 2000-06-20 |
DE69732535D1 (de) | 2005-03-24 |
AU5705198A (en) | 1998-07-31 |
KR20000062274A (ko) | 2000-10-25 |
CA2274581C (en) | 2004-02-10 |
JP3471025B2 (ja) | 2003-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3471025B2 (ja) | B7タンパク質の発現を調節するためのオリゴヌクレオチド組成物および方法 | |
JP4223687B2 (ja) | bcl−x発現のアンチセンスモジュレーション | |
JP2003501059A (ja) | B7タンパク質発現のアンチセンス調節 | |
US5801154A (en) | Antisense oligonucleotide modulation of multidrug resistance-associated protein | |
US6136603A (en) | Antisense modulation of interleukin-5 signal transduction | |
JP4168285B2 (ja) | インテグリンα4発現のアンチセンス調節 | |
JP2002526125A (ja) | 腫瘍壊死因子−α(TNF−α)発現のアンチセンス・オリゴヌクレオチド調節 | |
JP2002513593A (ja) | Cd40発現のアンチセンスモジュレーション | |
WO1999054341A1 (en) | Enhanced antisense modulation of icam-1 | |
US20020082227A1 (en) | Use of oligonucleotides for inhibition of complement activation | |
JP2001505432A (ja) | ヒト接着分子のアンチセンス阻害 | |
JP2002526095A (ja) | 腫瘍壊死因子受容体関連因子(traf)の発現のアンチセンスモジュレーション | |
WO1997044656A1 (en) | Compositions and methods for modulating type i interleukin-1 receptor expression | |
JP3590585B2 (ja) | Lfa−3のアンチセンス調節 | |
US20030171315A1 (en) | Oligonucleotide probes and primers comprising universal bases for therapeutic purposes | |
US7115580B1 (en) | Antisense modulation of B7 protein expression | |
US20030176374A1 (en) | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | |
JP2002519015A (ja) | Tnfr1発現のアンチセンスモジュレーション |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070912 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080912 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080912 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090912 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100912 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100912 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 8 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120912 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120912 Year of fee payment: 9 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130912 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |